These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37625591)

  • 1. A novel phosphorylation site involved in dissociating RAF kinase from the scaffolding protein 14-3-3 and disrupting RAF dimerization.
    Yu A; Nguyen DH; Nguyen TJ; Wang Z
    J Biol Chem; 2023 Oct; 299(10):105188. PubMed ID: 37625591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The AMPK inhibitor overcomes the paradoxical effect of RAF inhibitors through blocking phospho-Ser-621 in the C terminus of CRAF.
    Yuan J; Ng WH; Yap J; Chia B; Huang X; Wang M; Hu J
    J Biol Chem; 2018 Sep; 293(37):14276-14284. PubMed ID: 30030377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.
    Peng SB; Henry JR; Kaufman MD; Lu WP; Smith BD; Vogeti S; Rutkoski TJ; Wise S; Chun L; Zhang Y; Van Horn RD; Yin T; Zhang X; Yadav V; Chen SH; Gong X; Ma X; Webster Y; Buchanan S; Mochalkin I; Huber L; Kays L; Donoho GP; Walgren J; McCann D; Patel P; Conti I; Plowman GD; Starling JJ; Flynn DL
    Cancer Cell; 2015 Sep; 28(3):384-98. PubMed ID: 26343583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors.
    Monaco KA; Delach S; Yuan J; Mishina Y; Fordjour P; Labrot E; McKay D; Guo R; Higgins S; Wang HQ; Liang J; Bui K; Green J; Aspesi P; Ambrose J; Mapa F; Griner L; Jaskelioff M; Fuller J; Crawford K; Pardee G; Widger S; Hammerman PS; Engelman JA; Stuart DD; Cooke VG; Caponigro G
    Clin Cancer Res; 2021 Apr; 27(7):2061-2073. PubMed ID: 33355204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dimerization of the kinase ARAF promotes MAPK pathway activation and cell migration.
    Mooz J; Oberoi-Khanuja TK; Harms GS; Wang W; Jaiswal BS; Seshagiri S; Tikkanen R; Rajalingam K
    Sci Signal; 2014 Aug; 7(337):ra73. PubMed ID: 25097033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRAF dimerization with ARAF regulates KRAS-driven tumor growth.
    Venkatanarayan A; Liang J; Yen I; Shanahan F; Haley B; Phu L; Verschueren E; Hinkle TB; Kan D; Segal E; Long JE; Lima T; Liau NPD; Sudhamsu J; Li J; Klijn C; Piskol R; Junttila MR; Shaw AS; Merchant M; Chang MT; Kirkpatrick DS; Malek S
    Cell Rep; 2022 Feb; 38(6):110351. PubMed ID: 35139374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
    Poulikakos PI; Zhang C; Bollag G; Shokat KM; Rosen N
    Nature; 2010 Mar; 464(7287):427-30. PubMed ID: 20179705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analyses of the oncogenic BRAF
    Cope NJ; Novak B; Liu Z; Cavallo M; Gunderwala AY; Connolly M; Wang Z
    J Biol Chem; 2020 Feb; 295(8):2407-2420. PubMed ID: 31929109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.
    Jain P; Fierst TM; Han HJ; Smith TE; Vakil A; Storm PB; Resnick AC; Waanders AJ
    Oncogene; 2017 Nov; 36(45):6348-6358. PubMed ID: 28806393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An oncogenic mutant of RHEB, RHEB Y35N, exhibits an altered interaction with BRAF resulting in cancer transformation.
    Heard JJ; Phung I; Potes MI; Tamanoi F
    BMC Cancer; 2018 Jan; 18(1):69. PubMed ID: 29320991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erianin suppresses constitutive activation of MAPK signaling pathway by inhibition of CRAF and MEK1/2.
    Wang P; Jia X; Lu B; Huang H; Liu J; Liu X; Wu Q; Hu Y; Li P; Wei H; Liu T; Zhao D; Zhang L; Tian X; Jiang Y; Qiao Y; Nie W; Ma X; Bai R; Peng C; Dong Z; Liu K
    Signal Transduct Target Ther; 2023 Mar; 8(1):96. PubMed ID: 36872366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The CNK-HYP scaffolding complex promotes RAF activation by enhancing KSR-MEK interaction.
    Maisonneuve P; Sahmi M; Bergeron-Labrecque F; Ma XI; Queguiner J; Arseneault G; Lefrançois M; Kurinov I; Fronzes R; Sicheri F; Therrien M
    Nat Struct Mol Biol; 2024 Jul; 31(7):1028-1038. PubMed ID: 38388830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MEK drives BRAF activation through allosteric control of KSR proteins.
    Lavoie H; Sahmi M; Maisonneuve P; Marullo SA; Thevakumaran N; Jin T; Kurinov I; Sicheri F; Therrien M
    Nature; 2018 Feb; 554(7693):549-553. PubMed ID: 29433126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optogenetically controlled RAF to characterize BRAF and CRAF protein kinase inhibitors.
    Chatelle CV; Hövermann D; Müller A; Wagner HJ; Weber W; Radziwill G
    Sci Rep; 2016 Mar; 6():23713. PubMed ID: 27025703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK.
    Brennan DF; Dar AC; Hertz NT; Chao WC; Burlingame AL; Shokat KM; Barford D
    Nature; 2011 Apr; 472(7343):366-9. PubMed ID: 21441910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers.
    Rebocho AP; Marais R
    Oncogene; 2013 Jun; 32(26):3207-12. PubMed ID: 22926515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Active Ras induces heterodimerization of cRaf and BRaf.
    Weber CK; Slupsky JR; Kalmes HA; Rapp UR
    Cancer Res; 2001 May; 61(9):3595-8. PubMed ID: 11325826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural snapshots of RAF kinase interactions.
    Rezaei Adariani S; Buchholzer M; Akbarzadeh M; Nakhaei-Rad S; Dvorsky R; Ahmadian MR
    Biochem Soc Trans; 2018 Dec; 46(6):1393-1406. PubMed ID: 30381334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting CRAF kinase in anti-cancer therapy: progress and opportunities.
    Wang P; Laster K; Jia X; Dong Z; Liu K
    Mol Cancer; 2023 Dec; 22(1):208. PubMed ID: 38111008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.